Jin-Tao Huang
Overview
Explore the profile of Jin-Tao Huang including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
83
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wang Z, Xu X, Liu C, Huang J, Li W, Zhang S, et al.
J Med Imaging Radiat Oncol
. 2025 Feb;
PMID: 39981811
Objectives: To compare the long-term efficacy and safety of transjugular intrahepatic portosystemic shunt (TIPS) combined with concurrent antegrade embolization in treating portal hypertension with oesophagogastric variceal bleeding in patients with...
2.
Huang J, Hu D, Hong X, Zhou W, Shen J, Lv P, et al.
Eur Radiol Exp
. 2025 Feb;
9(1):21.
PMID: 39966235
Background: The objective of this study was to evaluate the therapeutic effectiveness and safety of transarterial chemoembolization (TACE) combined with programmed cell death-1 (PD-1) inhibitors and lenvatinib in the treatment...
3.
Zhou W, Huang J, Lu X, Hu D, Hong X, Wang F, et al.
J Hepatocell Carcinoma
. 2024 Dec;
11:2515-2524.
PMID: 39720263
Purpose: Camrelizumab and rivoceranib together provide a new first-line treatment approach for unresectable hepatocellular carcinoma (HCC). Meanwhile, transarterial chemoembolization (TACE) is an effective method for the local control of the...
4.
Qu X, Meng L, Lu X, Chen X, Li Y, Zhou R, et al.
Heliyon
. 2024 Jan;
10(1):e23686.
PMID: 38259960
Cuproptosis is a novel discovered mode of programmed cell death. To identify the molecular regulatory patterns related to cuproptosis, this study was designed for exploring the correlation between cuproptosis-related genes...
5.
Hu Z, Xu X, Wang Z, Huang J, Li W, Zhang S, et al.
J Hepatocell Carcinoma
. 2023 Nov;
10:2073-2082.
PMID: 38022730
Background: The CRAFITY (C-reactive protein and alpha-fetoprotein in immunotherapy) score has demonstrated prognostic significance in hepatocellular carcinoma (HCC) patients undergoing immunotherapy. The study aimed to validate accuracy of CRAFITY score...
6.
Huang J, Zhong B, Li W, Jiang N, Qian D, Hu Z, et al.
Abdom Radiol (NY)
. 2023 Nov;
49(3):900-907.
PMID: 38010526
Objectives: To estimate the safety and effectiveness of emergent transjugular intrahepatic portosystemic shunt (TIPS) creation for acute variceal bleeding (AVB) in cirrhotic patients with hepatocellular carcinoma (HCC). Materials And Methods:...
7.
Jiang J, Huang J, Zhong B, Wang W, Sun J, Wang Q, et al.
J Hepatocell Carcinoma
. 2023 Oct;
10:1629-1638.
PMID: 37791066
Background And Objectives: This study aimed to evaluate the efficacy and safety of transarterial chemoembolization (TACE) in patients with unresectable early or intermediate hepatocellular carcinoma (HCC) and Child-Pugh (CP)-B liver...
8.
Zhong B, Jiang J, Sun J, Huang J, Wang W, Wang Q, et al.
J Clin Transl Hepatol
. 2023 Sep;
11(6):1321-1328.
PMID: 37719966
Background And Aims: To validate prognostic performance of the China liver cancer (CNLC) staging system as well as to compare these parameters with those of the Barcelona Clinic Liver Cancer...
9.
Huang J, Zhong B, Li W, Zhang S, Shen J, Zhu X
Eur J Radiol
. 2023 Jun;
165:110944.
PMID: 37356217
Objectives: To evaluate the feasibility of computed tomography portal venography (CTPV) in the preoperative evaluation of emergent transjugular intrahepatic portosystemic shunt (TIPS) creation for cirrhotic patients with acute variceal bleeding...
10.
Huang J, Zhong B, Jiang N, Li W, Zhang S, Yin Y, et al.
J Hepatocell Carcinoma
. 2022 Dec;
9:1217-1228.
PMID: 36474670
Objective: This study aimed to evaluate the effectiveness and safety of transarterial chemoembolization (TACE) in combination with immune checkpoint inhibitors (ICIs) plus tyrosine kinase inhibitors (TKIs) (TACE+IT) versus ICIs plus...